(BFM Bourse) – Boiron returns to profit at the end of its first half. The Rhone laboratory is reaping the benefits of its diversification with the launch of new products. For the current year, Boiron anticipates an increase in sales in all geographic areas as well as a significant change in profitability.
Well underway for several months, the recovery of Boiron is confirmed. The laboratory’s efforts to reduce its dependence on homeopathic care, a market segment that had made the reputation of the Rhone group, have been bearing fruit for several quarters.
The laboratory’s latest publication once again shows an improvement in the group’s business after a very good start to 2022. The company thus achieved cumulative revenue over the first six months of the year of 256.76 million euros, up 35.2% and 32% at constant exchange rates. The increase in sales is distributed more or less equally between historic homeopathic specialties and new products, adds the Rhone laboratory.
Boiron specifies that the increase in sales observed in the first half concern all the geographical areas where the group operates. In France, revenues appreciated by 25.2% when they jumped by 47.6% internationally.
With the entry into force of the new law on the reimbursement of homeopathic care in France in 2021, the laboratory had been forced to change strategy with the launch of new products.
The laboratory has focused on innovation with the launch of food supplements, in vitro diagnostic devices, cosmetics and phytotherapy products. New homeopathic medicines have also enriched the range of Boiron, the laboratory released in the first quarter of a new homeopathic medicine for the symptoms of chickenpox, Varésol.
Revenues from the sale of these new products have thus increased significantly to reach 47 million euros, compared to 15 million euros in the first half of 2021, i.e. a dizzying increase of 190% over one year.
Boiron returns to profit
The growth in Boiron’s activity enabled operating profit to return to positive territory at the end of the past half-year. From an operating loss of 11.04 million euros in the first half of 2021, the Rhone group generated an operating profit of nearly 20 million euros as of June 30, 2022. of the group amounts to 12.52 million euros against a net loss group share of 9.51 million euros last year at the same time.
The group, which is counting on growth in its turnover in 2022 and a “significant evolution of profitability” (without giving more details), nevertheless remains vigilant to the evolution of the global health crisis. Boiron also says it is doing “everything” to ensure the availability of its medicines and its entire product line in a context of sustained inflation and tensions over certain energy and raw material supplies.
If Boiron loses 2.3% after this publication around 2:30 p.m., this decline does not affect the upward momentum observed on the file since the beginning of the year. The diversification carried out by Boiron after the delisting of homeopathy in France is appreciated, the title of the laboratory has gained nearly 30% since January 1st.
Sabrina Sadgui – ©2022 BFM Bourse
Are you following this action?
Receive all the information about BOIRON in real time: